View Older Stories
-
Sanofi (SNY) Tops Q4 EPS by 69c; offers outlook
-
Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'
-
UBS Downgrades Sanofi (SAN:FP) (SNY) to Neutral
-
FDA delays reviews of Sanofi's Tzield and Disc Medicine's bitopertin
-
Sanofi (SNY) CEO: expect to maintain double digit growth for next half decade - JPM Conference
-
Sanofi (SNY) January 50 calls active into the annual J.P. Morgan Healthcare Conference
-
FDA approves Cablivi for rare blood disorder in kids
-
FDA approves Sanofi's Cablivi for pediatric blood clotting disorder
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
TD Cowen Reiterates Hold Rating on Sanofi (SNY)
-
TD Cowen Reiterates Hold Rating on Sanofi (SAN:FP) (SNY)
-
BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Sanofi wins EU approval for Wayrilz to treat immune thrombocytopenia
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Sanofi reaches deal with US government to cut drug prices
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
Dren Bio secures $100 million from Sanofi for B-cell therapy collaboration
-
Guggenheim Downgrades Sanofi (SNY) to Neutral
-
Guggenheim Downgrades Sanofi (SAN:FP) (SNY) to Neutral
-
Valuation in this big pharma stock continues to be attractive: analyst
-
Increasing unusual put option volume: BAX SNY XP GPN AVXL CAPR EXE WY HROW VG
-
Novavax completes US marketing transfer to Sanofi, receives $25 million
-
Sanofi (SNY) Tops Q3 EPS by 72c
-
Sanofi earnings preview: Stable quarter expected
-
Sanofi’s third-quarter results seen steady as margin outlook draws focus
-
Sanofi high-dose flu vaccine cuts hospitalizations 32% in older adults
-
Revvity partners with Sanofi to develop type 1 diabetes screening test
-
Novavax expands Sanofi license for Matrix-M adjuvant use
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
Berenberg Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Sanofi expands insulin program to $35 monthly cap for all US patients
-
FDA removes safety restrictions for Sanofi thyroid cancer drug
-
Sanofi (SNY) ordered to pay EUR 150.7M in France over anti-competitive behaviour
-
BofA sees attractive growth in this large-cap pharma stock
-
Morgan Stanley Upgrades Sanofi (SNY) to Overweight
-
Analysts postive on Nektar opportunity after Sanofi data
-
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
-
Regeneron (REGN) Shares Decline on the Open
-
BofA Securities Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Leerink Partners Reiterates Outperform Rating on Sanofi (SNY)
-
Sanofi reports results from atopic dermatitis trial of amlitelimab
-
Deutsche Bank Upgrades Sanofi (SAN:FP) (SNY) to Buy
-
Here's how Sanofi (SNY) NPV could move on upcoming Phase 3 readouts
-
Sanofi (SNY) halts Praluent supply in China due to limited availability
-
JPMorgan Upgrades Sanofi (SAN:FP) (SNY) to Overweight
-
Increasing unusual call option volume: CWAN PRMB UNIT SNY PGEN HLF NB VRNT FE HESM
-
Sanofi (SNY) Reports Q2 EPS of EUR1.59; offers guidance

